These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31468315)

  • 41. Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD.
    Fabbri LM; Kerwin EM; Spangenthal S; Ferguson GT; Rodriguez-Roisin R; Pearle J; Sethi S; Orevillo C; Darken P; St Rose E; Fischer T; Golden M; Dwivedi S; Reisner C
    Respir Res; 2016 Sep; 17(1):109. PubMed ID: 27586537
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naïve patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trials.
    Zheng J; Xu JF; Jenkins M; Assam PN; Wang L; Lipworth BJ
    Respir Res; 2020 Mar; 21(1):69. PubMed ID: 32164675
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease.
    Carter NJ
    Drugs; 2013 May; 73(7):741-53. PubMed ID: 23677802
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and Safety of Inhaled Glycopyrronium Bromide in COPD: A Randomized, Parallel Group, Dose-Ranging Study (GLIMMER).
    Kerwin E; Feldman G; Pearle J; De La Cruz L; Edwards M; Beaudot C; Georges G
    COPD; 2021 Apr; 18(2):181-190. PubMed ID: 33709856
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD - A randomised, multicentre, crossover trial.
    Watz H; Mailänder C; May C; Baier M; Kirsten AM
    Pulm Pharmacol Ther; 2017 Feb; 42():13-20. PubMed ID: 27940287
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug Delivery from an Innovative LAMA/LABA Co-suspension Delivery Technology Fixed-Dose Combination MDI: Evidence of Consistency, Robustness, and Reliability.
    Doty A; Schroeder J; Vang K; Sommerville M; Taylor M; Flynn B; Lechuga-Ballesteros D; Mack P
    AAPS PharmSciTech; 2018 Feb; 19(2):837-844. PubMed ID: 29019170
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide.
    Mantero M; Radovanovic D; Santus P; Blasi F
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2319-2333. PubMed ID: 30104872
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial.
    Noonan M; Rosenwasser LJ; Martin P; O'Brien CD; O'Dowd L
    Drugs; 2006; 66(17):2235-54. PubMed ID: 17137405
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison.
    Medic G; Lindner L; van der Weijden M; Karabis A
    Adv Ther; 2016 Mar; 33(3):379-99. PubMed ID: 26883661
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.
    Babu KS; Morjaria JB
    Ther Adv Respir Dis; 2015 Apr; 9(2):56-68. PubMed ID: 25754881
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
    Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
    Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
    Kerwin EM; Siler TM; Arora S; Darken P; Rose E; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1483-1494. PubMed ID: 29773947
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term safety of glycopyrrolate/eFlow
    Ferguson GT; Goodin T; Tosiello R; Wheeler A; Kerwin E
    Respir Med; 2017 Nov; 132():251-260. PubMed ID: 28919143
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
    Farne HA; Cates CJ
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study.
    Ferguson GT; Papi A; Anzueto A; Kerwin EM; Cappelletti C; Duncan EA; Nyberg J; Dorinsky P
    Eur Respir J; 2018 Sep; 52(3):. PubMed ID: 30220648
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
    Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
    Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Consistent Pulmonary Drug Delivery with Whole Lung Deposition Using the Aerosphere Inhaler: A Review of the Evidence.
    Usmani OS; Roche N; Jenkins M; Stjepanovic N; Mack P; De Backer W
    Int J Chron Obstruct Pulmon Dis; 2021; 16():113-124. PubMed ID: 33500616
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial.
    Rhee CK; Park HY; Park JW; Lee JH; Kim TH; Lee SW; Jung JY; Kim S; Hwang YI; Jung KS
    Trials; 2017 Feb; 18(1):80. PubMed ID: 28228162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond.
    Rabe KF
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):685-698. PubMed ID: 28443352
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Formoterol: a review of its use in chronic obstructive pulmonary disease.
    Cheer SM; Scott LJ
    Am J Respir Med; 2002; 1(4):285-300. PubMed ID: 14720051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.